Contraception choice for HIV positive women

Sexually Transmitted Infections

Volumn 80, Issue 3, 2004, Pages 167-173

  Mitchell, H S ^a   Stephens, E ^b  

^a Camden Primary Care Trust   (United Kingdom)

^b Margaret Pyke Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIRETROVIRUS AGENT; CONTRACEPTIVE AGENT; COPPER; DESOGESTREL; DIDANOSINE; EFAVIRENZ; ENZYME; ENZYME INDUCING AGENT; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL VALERATE PLUS NORETHISTERONE ENANTATE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETONOGESTREL; GESTAGEN; GRISEOFULVIN; HORMONE; INDINAVIR; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NEVIRAPINE; NONOXINOL; NORETHISTERONE ENANTATE; RIFABUTIN; RIFAMPICIN; RITONAVIR; SPERMICIDAL AGENT; STAVUDINE; TOGLIZATONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CONDOM; CONTRACEPTION; CONTRACEPTIVE DEVICE; COUNSELING; DISEASE TRANSMISSION; DRUG USE; FAMILY; FEMALE STERILIZATION; FOLLOW UP; GENDER; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTRAUTERINE CONTRACEPTIVE DEVICE; MALE STERILIZATION; MEDICAL DECISION MAKING; MENSTRUATION; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; REPRODUCTION; REVIEW; RISK; SEXUAL TRANSMISSION; VAGINA BLEEDING; VAGINA EPITHELIUM; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; CHOICE BEHAVIOR; CONDOMS; CONDOMS, FEMALE; CONTRACEPTION BEHAVIOR; CONTRACEPTIVES, ORAL, HORMONAL; COUNSELING; FEMALE; HIV INFECTIONS; HUMANS; INTRAUTERINE DEVICES; MIDDLE AGED; SPERMATOCIDAL AGENTS;

EID: 2942515938     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.2003.008441     Document Type: Review

References (95)

1. UNAIDS/WHO. AIDS epidemic update. Geneva: UNAIDS/02.46E, December 2002.
2. International Planned Parenthood Federation. IMAP statement on hormonal methods of contraception. IPPF Medical Bulletin 2002;336:No 5 Oct.
3. United Nations Population Division Statistics Department of Economic and Social Affairs. World contraceptive use. June 2001.
4. UNICEF. Statistics fertility and contraceptive use 2000.
5. Bongaarts J, Westoff CF. The potential role of contraception in reducing abortion. Studies Fam Plann 2000;31:193-202.
6. Playle JF. Concepts of compliance: understandings and approaches. Br J Fam Plann 2000;26:213-19.
7. Gazmararian JA, Parker RM, Baker DW. Reading skills and family planning knowledge and practices in a low-income managed-care population. Obstet Gynaecol 1999;93:239-44.
8. UNAIDS. Sexual behavioural change for HIV: where have the theories taken us? Geneva: UNAIDS/99.27E, June 1999.
9. Ryder RW, Batter VL, Nsuami M, et al. Fertility rates in 238 HIV-1 seropositive women in Zaire followed for 3 years postpartum. AIDS 1991;5:1521-7.
10. Allen S, Serufilira A, Gruber V, et al. Pregnancy and contraception use among urban Rwandan women after testing and counselling. Am J Public Health 1993;83:705-10.
11. Sunderland A, Minkoff HL, Handte J, et al. The impact of human immunodeficiency virus serostatus on reproductive decisions of women. Obstet Gynecol 1992;79:1027-31.
12. Dabis F, Ekpini ER. HIV-1/AIDS and maternal and child health in Africa. Lancet 2002;359:2097-104.
13. Ross A, Morgan D, Lubega R, et al. Reduced fertility associated with HIV: the contribution of pre-existing subfertility. AIDS 1999;13:2133-41.
14. Selwyn PA, Schoenbaum EE, Davenny K, et al. Prospective study of human immunodeficiency virus and pregnancy outcome in intravenous drug users. JAMA 1989;261:1289-94.
15. Wilson T, Massad LS, Riester KA, et al. Sexual, contraceptive, and drug use behaviours of women with HIV and those at high risk for infection: results from the Women's Interagency HIV Study. AIDS 1999;13:591-8.
16. De Vincenzi I, Jadand C, Couturier E, et al. Pregnancy and contraception in a French cohort of HIV-infected women. AIDS 1997;11:333-8.
17. Murphy D, Lynch M, Desmond N, et al. Contraceptive practices in HIV seropositive females in Ireland. Int J STD AIDS 1993;4:107-9.
18. Hankins C, Tran T, Lapointe N, et al. Sexual behaviour and pregnancy outcome in HIV-infected women. J AIDS Hum Rep 1998;18:479-87.
19. Desgréos-du-Loû A, Msellati P, Viho I, et al. Contraceptive use, protected sexual intercourse and incidence of pregnancies among African HIV-infected women. DITRAME ANRS 049 Project, Abidjan 1995-2000. Int J STD AIDS 2002;13:462-8.
20. Hankins C, Tran T, Lapointe N, et al. Sexual behaviour and pregnancy outcome in HIV-infected women. J AIDS Hum Rep 1998;18:479-87.
21. Magalhaes J, Amaral E, Giraldo PC, et al. HIV Infection in women: impact on contraception. Contraception 2002;66:87-91.
22. BHIVA. Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission. London: Br HIV Assoc (BHIVA) 2001 (www.bhiva.org).
23. RCOG. National study of HIV in pregnancy. Newsletter 55, July 2003.
24. Davis K, Weller S. The effectiveness of condoms in reducing heterosexual transmission of HIV. Family Planning Perspectives 1999;31:272-9.
25. Steiner MJ, Cates W Jr. The real problem with male condoms is non-use. Sex Transm Dis 1999;26:459-62.
26. Marks G, Burris S, Petersen TA. Reducing sexual transmission of HIV from those who know they are infected: the need for personal and collective responsibility. AIDS 1999;13:297-306.
27. Cates W, Stone KM. Family planning, sexually transmitted diseases and contraceptive choice: a literature update-Part I. Fam Plann Perspect 1992;24:75-84.
28. Trussel J, Warner DL, Hatcher RA. Condom slippage and breakage rates. Family Planning Perspectives 1992;24:20-3.
29. International Planned Parenthood Federation (IPPF). International Medical Advisory Panel (IMAP) statement on dual protection against unwanted pregnancy and sexually transmitted infections, including HIV. IPPF Medical Bulletin 2000;34:No 4 Aug.
30. Carlin EM, Boag FC. Women, contraception and STDs including HIV. Int J STD AIDS 1995;6:373-86.
31. UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Reproductive Health and Research, WHO. HIV/AIDS makes dual protection a must. Progress in Reproductive Health Research Quarterly Newsletter 2002;No 59.
32. Daly CC, Helling-Giese GE, Mati JK, et al. Contraceptive methods and the transmission of HIV: implications for family planning. Genitourin Med 1994;70:110-17.
33. Bounds W, et al. A Female condom (Femshield): a study of its user-acceptability. Br J Fam Plann 1988;14:83-7.
34. Farr G, et al. Contraceptive efficacy and acceptability of the female condom. Am J Pub Health 1994;84:1960-4.
35. Trussell J. Contraceptive efficacy of the Reality female condom. Contraception 1998;58:147-8.
36. Diaz T, Scable B, Chu S. Relationship between use of condoms and other forms of contraception among HIV-infected women. Obstet Gynaecol 1995;86:277-82.
37. Frank ML, Bateman L, Poindexter AN. Planned condom use by women with Norplant implants. Adv Contracept 1993;9:227-32.
38. Clark RA, Kissinger P, Bedimo A, et al. Determination of factors associated with condom use among women infected with human immunodeficiency virus. Int J STD AIDS 1997;8:229-33.
39. Allen S, Meinzen-Derr J, Kautzman M, et al. Sexual behaviour of HIV discordant couples after HIV counselling and testing. AIDS 2003;17:733-40.
40. de Vincenzi I, et al. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners N Engl J Med 1994;331:341-6.
41. Feldblum, Welsh MJ, Steiner MJ. Don't overlook condoms for HIV prevention. Sex Transm Infect 2003;79:268-9.
42. Kalichman SC, Rompa D, Cage M. Factors associated with female condom use among HIV-seropositive women. Int J STD AIDS 2000;11:798-803.
43. International Planned Parenthood Federation. IPPF Medical Bulletin 2001;35:No 1 Feb.
44. WHO. Information update: considerations regarding the reuse of the female condom, July 2002 (www.who.int/reproductive-health/rtis/reuse.en.html).
45. Wilkinson D, Tholandi M, Ramjee G, et al. Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infect Dis 2002;2:613-17.
46. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002;360:971-7.
47. WHO/CONRAD Technical Consultation on Nonoxynol-9. Geneva: WHO, October 2001, Summary Report.
48. WHO. Medical eligibility criteria for contraceptive use, 2nd ed. Available for download on the internet at www.who.int/reproductive-health/ publications/ RHR_00_2_medical eligibility_cr.
49. New Product Review. Desogestrel-only pill (Cerazerte). Clinical Effectiveness Unit. Aberdeen: Faculty of Family Planning and Reproductive Health Care, April 2003.
50. EVRA (norelgestromin/ethinyl oestradiol transdermal system) product information. Janssen-Cilag International NV, Belgium. April 2003.
51. Martin HL Jr, Nyange PM, Richardson BA, et al. Hormonal contraception, sexually transmitted diseases and risk of heterosexual transmission or human immunodeficiency virus type 1. J Infect Dis 1998;178:1053-9.
52. Clark RA, Kissinger P, Williams T. Contraceptive and sexually transmitted diseases protection among adult and adolescent women infected with human immunodeficiency virus. Int J STD AIDS 1996;7:439-42.
53. Cates W, Stone KM. Family Planning, sexually transmitted diseases and contraceptive choice: a literature update - Part II. Fam Plann Perspect 1992;24:122-8.
54. Sinei SKA, Fortney JA, Kigondu CS, et al. Contraceptive use and HIV infection in Kenyan family planning clinic attenders. Int J STD AIDS 1996;7:65-70.
55. Mati JKG, Hunter DJ, Maggwa BM, et al. Contraceptive use and the risk of HIV infection in Nairobi, Kenya. Int J Gynecol Obstet 1995;48:61-7.
56. Howe JE, Minkoff HL, Duerr AC. Contraceptives and HIV. AIDS 1994;8:861-71.
57. Stephenson JM. Systematic review of hormonal contraception and risk of HIV transmission: when to resist meta-analysis. AIDS 1998;12:545-53.
58. Kiddugavu M, Makumbi F, Wawer MJ, et al. Hormonal contraceptive use and HIV-1 infection in a population-based cohort in Rakai, Uganda. AIDS 2003;17:233-40.
59. Marx PA, Spira Al, Gettie A, et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 1996;2:1084-9.
60. Kraehenbuhl J-P, Wain-Hobson S. Breaching barriers. Nat Med 1996;2:1080-2.
61. Moss GB, Clemetson D, D'Costa L, et al. Association of cervical ectopy with heterosexual transmission of human immunodeficiency virus: results or a study of couples in Nairobi, Kenya. J Infect Dis 1991;164:588-91.
62. Mostad SB, Overbought J, DeVange DM, et al. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet 1998;350:922-7.
63. Fiore JR, Suligoi B, Saracino A, et al. Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS 2003;17:2169-76.
64. Kovacs A, Wasserman SS, Burns D, et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001;358(9293):1593-601.
65. Bigrigg A, Evans M, Gbolade B, et al. Depo Provera. Position paper on clinical use, effectiveness and side effects. Review article. Br J Fam Plann 1999;25:69-76 and erratum 1999;26:52-3.
66. Edwards JE, Moore A. Implanon: a review of clinical studies. Br J Fam Plann 1999;24:S3-16.
67. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing IUDs during five years of use: a randomised comparative trial. Contraception 1994;49:56-72.
68. Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol 1990;97:690-4.
69. Duckitt K, Shaw RW. Is medical management of menorrhagia obsolete? Br J Obstet Gynaecol 1998;108:569-72.
70. Sturridge F, Guillebaud J. Gynaecological aspects of the levonorgestrel-releasing intrauterine system Br J Obstet Gynaecol 1997;104:285-9.
71. Thonneau P, Goulard H, Goyaux N. Risk factors for infrauterine device failure: a review. Contraception 2001;64:33-7.
72. Richardson B, Morrison CS, Sekadde-Kigondu C, et al. Effect of intrauterine device use on cervical shedding of HIV-1 DNA. AIDS 1999;13:2091-7.
73. European Study Group on Heterosexual transmission of HIV. Comparison of female to male and male to female transmission of HIV in 536 stable couples. BMJ 1992;304:809-13.
74. Farley TM, Rosenburg MJ, Rowe PJ, et al. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992;339:1005-8.
75. Hubacher D, Lara-Ricalde R, Taylor DJ, et al. Use of Copper Intruferine Devices and the Risk of Tubal Infertility among Nulligravid Women. N Enql J Med 2001;345:561-7.
76. Walsh T, Grimes D, Frezieres R, et al. Randomised controlled trial of prophylactic antibiotics before insertion of intrauterine devices. Lancet 1998;351:1005-9.
77. 31 st Study Group. Recommendations arising from the 31st Study Group: the prevention of pelvic infection. J Br Fertil Soc 1997;2:16-17.
78. Sinei SK, Morrison CS, Sekadde-Kigondu C, et al. Complications of use of intrauterine devices among HIV-1 infected women. Lancet 1998;351:1238-41.
79. RCOG. National evidence-based clinical guidelines. Sterilisation-male and female www.rcog.org.uk.
80. Von Hertzen H, Piaggio G, Ding J, et al. Low dose Mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO mulitcentre randomised trial. Lancet 2002;360:1803-10.
81. Olaitan A, Madge S, Reid W, et al. Contraceptive use, and knowledge of postcoital contraception amongst HIV-infected women: a comparison with an HIV negative population. Br J Fam Plann 1996;22:127.
82. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001;344:984-96.
83. Ouellett D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmokinetics of ethinyl oestradiol in healthy female volunteers. Br J Pharmacol 1998;46:111-16.
84. Hoffmann-Lo Roche Ltd, Basle, Switzerland/Agouron Pharmaceutical Inc, La Jolla, USA. Data on file: Viracept (nelfinavir mesylate), Study AG. 1343-526.
85. Kaletra Product Information, Abbott Laboratories, 2000.
86. Mildvan D, Yarrish R, Hutman H, et al. Viramune (nevirapine) and Ortho-Novum 1/35 (ethinyl oestradiol/norethindrone) Interaction Study in HIV-1 infected Women. Abstract #89 Boehringer Ingelhin Pharmaceuticals, Inc, Ridgefield, CT, USA.
87. Sue N. Senior Medical Information Pharmacist, Bristol-Myers Squibb Pharmaceuticals Ltd. Medical Information Dept. Personal communication, Feb, 2003.
88. Indinivar (Crixivan) Product Information, Merck Sharp 1999.
89. Dickinson BD, Altman RD, Nielsen N, et al. Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol 2001;98:853-60.
90. Breckenridge A. Important interactions between St John's Wort (Hypericum perforatum) preparations and prescribed medicines. London: Committee on Safety of Medicines, 29 Feb 2000.
91. De Souza A, Brechin S, Penney G, from the Clinical Effectiveness Unit (CEU) The members' enquiry service: frequently asked questions. Br J Fam Plann 2003;29:225-6.
92. Elliman A. Interactions with hormonal contraception. FACT review article. BrJ Fam Plann 2000;26:109-11.
93. Bounds W, Guillebaud J. Observational series on women using the contraceptive Mirena concurrently with anti-epileptic and other enzyme-inducing drugs. Br J Fam Plann 2002;28:78-80.
94. Implanon Product Information 2002 Organon Laboratories Ltd.
95. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FFPRHC Guidance. Emergency Contraception (April 2003).